BridgeBio Pharma, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
BridgeBio Pharma, Inc. (BBIO) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $4.19 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2025-02-20
- BridgeBio Pharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2024-12-31 was $10.80M, a 64.35% increase year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2024-09-30 was -$5.52M.
- BridgeBio Pharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2024-06-30 was $166.00K, a 98.45% decline year-over-year.
- BridgeBio Pharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2024-03-31 was -$1.26M.
- BridgeBio Pharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $4.19M, a 19.11% increase from fiscal 2023.
- BridgeBio Pharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $3.52M.
- BridgeBio Pharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$7.73M, a 154.57% decline from fiscal 2021.
- BridgeBio Pharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was $14.16M, a 69.93% increase from fiscal 2020.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $5.28M derived: sum of 2 quarters · filed 2025-02-20 | $5.45M derived: sum of 3 quarters · filed 2025-02-20 | $4.19M 10-K · filed 2025-02-20 | ||||
| 2024-09-30 | -$5.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$5.36M derived: sum of 2 quarters · filed 2024-11-12 | -$6.61M 10-Q · filed 2024-11-12 | -$40.00K derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2024-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.09M 10-Q · filed 2024-08-01 | $5.48M derived: sum of 3 quarters · filed 2025-02-20 | -$1.90M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2024-03-31 | -$1.26M 10-Q · filed 2024-05-02 | $5.32M derived: sum of 2 quarters · filed 2025-02-20 | -$2.07M derived: sum of 3 quarters · filed 2025-02-20 | $8.63M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-12-31 | $6.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$813.00K derived: sum of 2 quarters · filed 2025-02-20 | $9.89M derived: sum of 3 quarters · filed 2025-02-20 | $3.52M 10-K · filed 2025-02-20 | ||||
| 2023-09-30 | -$7.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.32M derived: sum of 2 quarters · filed 2024-11-12 | -$3.06M 10-Q · filed 2024-11-12 | -$12.03M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-06-30 | $10.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $4.33M 10-Q · filed 2024-08-01 | -$4.64M derived: sum of 3 quarters · filed 2025-02-20 | -$11.18M derived: sum of 4 quarters · filed 2025-02-20 | ||||
| 2023-03-31 | -$6.37M 10-Q · filed 2024-05-02 | -$8.60M 10-Q · filed 2023-05-04 | -$15.34M derived: sum of 2 quarters · filed 2025-02-20 | -$21.89M derived: sum of 3 quarters · filed 2025-02-20 | -$11.22M derived: sum of 4 quarters · filed 2025-02-20 | |||
| 2022-12-31 | -$8.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$15.51M derived: sum of 2 quarters · filed 2025-02-20 | -$4.85M derived: sum of 3 quarters · filed 2025-02-20 | -$7.73M 10-K · filed 2025-02-20 | -$2.73M 10-K · filed 2023-02-23 | |||
| 2022-09-30 | -$6.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $4.12M derived: sum of 2 quarters · filed 2023-11-02 | $1.24M 10-Q · filed 2023-11-02 | $3.80M 10-Q · filed 2022-11-03 | $17.03M derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2022-06-30 | $10.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $7.79M 10-Q · filed 2023-08-03 | $8.39M 10-Q · filed 2022-08-04 | $23.58M derived: sum of 3 quarters · filed 2024-02-22 | $19.35M derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2022-03-31 | -$2.88M 10-Q · filed 2023-05-04 | $12.91M derived: sum of 2 quarters · filed 2024-02-22 | $8.68M derived: sum of 3 quarters · filed 2024-02-22 | $14.82M derived: sum of 4 quarters · filed 2024-02-22 | ||||
| 2021-12-31 | $15.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $11.56M derived: sum of 2 quarters · filed 2024-02-22 | $17.70M derived: sum of 3 quarters · filed 2024-02-22 | $14.16M 10-K · filed 2024-02-22 | $12.01M 10-K · filed 2022-02-25 | |||
| 2021-09-30 | -$4.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.91M derived: sum of 2 quarters · filed 2022-11-03 | -$1.63M 10-Q · filed 2022-11-03 | $1.82M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $6.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.60M 10-Q · filed 2022-08-04 | $6.04M derived: sum of 3 quarters · filed 2023-02-23 | $5.59M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | -$3.54M 10-Q · filed 2022-05-05 | -$95.00K derived: sum of 2 quarters · filed 2023-02-23 | -$544.00K derived: sum of 3 quarters · filed 2023-02-23 | $4.78M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $3.00M derived: sum of 2 quarters · filed 2023-02-23 | $8.32M derived: sum of 3 quarters · filed 2023-02-23 | $8.34M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | -$449.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $4.88M derived: sum of 2 quarters · filed 2021-11-04 | $4.89M 10-Q · filed 2021-11-04 | $4.53M derived: sum of 4 quarters · filed 2022-02-25 | ||||
| 2020-06-30 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $5.34M 10-Q · filed 2021-08-05 | $4.97M derived: sum of 3 quarters · filed 2022-02-25 | $7.44M derived: sum of 4 quarters · filed 2022-02-25 | ||||
| 2020-03-31 | $15.00K 10-Q · filed 2021-05-06 | -$349.00K derived: sum of 2 quarters · filed 2022-02-25 | $2.12M derived: sum of 3 quarters · filed 2022-02-25 | $754.00K derived: sum of 4 quarters · filed 2022-02-25 | ||||
| 2019-12-31 | -$364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $2.10M derived: sum of 2 quarters · filed 2022-02-25 | $739.00K derived: sum of 3 quarters · filed 2022-02-25 | $1.46M 10-K · filed 2022-02-25 | $1.53M 10-K · filed 2020-03-03 | |||
| 2019-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.10M derived: sum of 2 quarters · filed 2020-11-05 | $1.83M 10-Q · filed 2020-11-05 | $2.69M 10-Q · filed 2019-11-08 | $3.76M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | -$1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$639.00K 10-Q · filed 2020-08-11 | $1.30M derived: sum of 3 quarters · filed 2021-02-25 | |||||
| 2019-03-31 | $723.00K 10-Q · filed 2020-05-14 | $2.66M derived: sum of 2 quarters · filed 2021-02-25 | ||||||
| 2018-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.10M 10-K · filed 2021-02-25 | $2.92M 10-K · filed 2020-03-03 | |||||
| 2018-09-30 | $1.16M 10-Q · filed 2019-11-08 | |||||||
| 2017-12-31 | $356.00K 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |